Molnupiravir or nirmatrelvir-ritonavir versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
<p><strong>Background:</strong> Molnupiravir and nirmatrelvir-ritonavir (Paxlovid) are oral antivirals that have been proposed as treatments for patients admitted to hospital with COVID-19.</p> <br> <p><strong>Methods:</strong> In this randomised, cont...
Main Authors: | RECOVERY Collaborative Group, Horby, PW, Staplin, N, Peto, L, Emberson, JR, Campbell, M, Pessoa-Amorim, G, Basnyat, B, Thwaites, L, Van Doorn, R, Hamers, RL, Nel, J, Amuasi, J, Stewart, R, Ghosh, D, Hamilton, F, Desai, P, Easom, N, Majumdar, J, Hine, P, Chadwick, D, Cooke, G, Sharp, S, Esmail, H, Baillie, JK, Buch, MH, Faust, SN, Jaki, T, Jeffery, K, Juszczak, E, Knight, M, Lim, WS, Montgomery, A, Mukherjee, A, Mumford, A, Rowan, K, Thwaites, G, Mafham, M, Haynes, R, Landray, MJ |
---|---|
Format: | Internet publication |
Language: | English |
Published: |
2024
|
Similar Items
-
Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19
by: Samuel Theodorus Sutanto, et al.
Published: (2022-12-01) -
Molnupiravir and Nirmatrelvir/Ritonavir: Tolerability, Safety, and Adherence in a Retrospective Cohort Study
by: Maria Mazzitelli, et al.
Published: (2023-01-01) -
Comparing Molnupiravir to Nirmatrelvir/Ritonavir (Paxlovid) in the Treatment of Mild-to-Moderate COVID-19 in Immunocompromised Cancer Patients
by: Andrea J. Haddad, et al.
Published: (2024-03-01) -
Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models
by: Robert M. Cox, et al.
Published: (2023-08-01) -
Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study
by: Ivan Gentile, et al.
Published: (2022-10-01)